###### Strengths and limitations of this study

-   This will be the first double-blind randomised controlled trial to investigate the efficacy and safety of pneumoperitoneum preconditioning in patients with renal tumours after laparoscopic partial nephrectomy.

-   ^99m^Tc-diethylenetriaminepentaacetic acid (^99m^Tc-DTPA) renal scintigraphy will be used to detect the change in glomerular filtration rate of unilateral impaired kidney.

-   Standard Protocol Items Recommendations for Interventional Trials checklist guidelines were followed when we drafted this protocol.

-   Limitations may be the relatively small sample size, short follow-up time, and not fully controlled warm ischaemia time during surgery.

Introduction {#s1}
============

Partial nephrectomy (PN) has become the standard surgical option for small renal tumours, which can preserve the maximum functional renal tissues on the basis of complete tumour removal.[@R1] Compared with traditional open operation, laparoscopic PN (LPN) can be more acceptable for the merits of minimal invasion and rapid recovery.[@R3] In most cases, the renal artery needs to be occluded during LPN to facilitate the surgery, which can result in renal ischaemia reperfusion injury (IRI) and affect the postoperational renal function.[@R4] Moreover, the increase of intra-abdominal pressure in LPN can decrease the blood ﬂow of abdominal viscera including kidney, and further aggravate the renal IRI.[@R6] Several strategies have been proposed to reduce renal IRI during LPN.[@R7] However, most methods are relatively complicated to implement or merely limited to surgical expertise. Therefore, an effective and feasible strategy is urgently warranted to prevent renal function after LPN.

Ischaemic preconditioning (IP) is a novel non-pharmacological approach, during which the target organ is conditioned with a brief episode of ischaemia and reperfusion prior to the subsequent prolonged ischaemic insult, and it has been confirmed effective in the alleviation of renal IRI.[@R10] However, the preoperative administration of IP through clamping the renal artery would be impractical to apply. Pneumoperitoneum preconditioning (PP) is one type of IP, and the transient periods of ischaemia and reperfusion during PP are executed by mechanical insufﬂation and desufﬂation, which can be relatively more safe and feasible than artery clamping.[@R6] Numerous animal researches have been conducted to detect the protective role of PP on organ IRI and explore the potential mechanisms.[@R13] Unfortunately, the utilisation of PP is rarely practised in clinical setting.

Therefore, we designed a randomised controlled trial (RCT) to assess the short-term and long-term renoprotective role of PP in patients undergoing LPN, and observe its effect on the other abdominal organs.

Methods and analysis {#s2}
====================

Study design {#s2-1}
------------

The present study will be a randomised, prospective, double-blind and parallel controlled clinical trial based on a single centre, and has already been successfully registered at ClinicalTrials.gov. The included participants in this study will be patients with renal tumours undergoing elective LPN between 2019 and 2020 in Nanjing First Hospital, Nanjing Medical University. Eligible patients will be randomly assigned to control group or PP group with a 1:1 ratio, and the follow-up will last for 6 months. A brief flow diagram of our study protocol is presented in [figure 1](#F1){ref-type="fig"}. This study protocol has been designed and written in accordance with the Standard Protocol Items Recommendations for Interventional Trials 2013 Checklist.[@R15]

![Schematic flow chart of the study. ALT, alanine transaminase; AMS, amylase; Cys C, cystatin C; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; I-FABP, intestinal fatty acid binding protein; PP, pneumoperitoneum preconditioning; SCr, serum creatinine.](bmjopen-2019-032002f01){#F1}

Protocol version {#s2-2}
----------------

Issue date: 9 January 2019; version identifier: NFH20180205; number of protocol amendments: 5; initial version: 16 February 2018. First modification: 3 March 2018, the procedure of PP was altered to three cycles of 5 min insufﬂation and 5 min desufﬂation. Second modification: 10 May 2018, the inclusion criteria regarding renal tumour was changed to stage T1a and tumour ≤4 cm in diameter, and the corresponding exclusion criteria was also reset (tumour \>4 cm in diameter). Third modification: 5 August 2018, alanine transaminase (ALT), serum amylase (AMS) and intestinal fatty acid binding protein (I-FABP) were added as secondary endpoints. Fourth modification: 22 November 2018, the estimation of sample size was optimised. Fifth modification: 9 January 2019, optimising of inserted figures and formula.

Eligibility criteria {#s2-3}
--------------------

### Inclusion criteria {#s2-3-1}

\(1\) Male and female patients aged 18 years and older; (2) patients with benign or malignant renal tumours who choose LPN as the surgical method; (3) the renal tumour must be stage T1a and no more than 4 cm in diameter (assessed by MRI/CT); (4) the unilateral renal tumour, and another contralateral renal function reveal normal (renal function \>40% as determined by radionuclide scintigraphy); (5) patients volunteer for this study and provided written informed consent.

### Exclusion criteria {#s2-3-2}

\(1\) Large tumours (tumours \>4 cm in diameter); (2) severe renal insufficiency (glomerular filtration rate (GFR)\<30 mL/min/1.73 m^2^) or needing preoperative haemodialysis or peritoneal dialysis; (3) patients with severe cardiopulmonary dysfunction; (4) pregnant women; (5) patients with other malignant tumours; (6) patients with a history of other abdominal viscera operations within 1 year (open or under laparoscope); (7) American Society of Anesthesiologists Physical Status Classification System for patients (ASA)\>Ⅲ; (8) patients who have had a renal transplantation.

Recruitment, randomisation and allocation {#s2-4}
-----------------------------------------

All the participating researchers will be systematically trained before the beginning of the trial. The screening of the patients will be conducted by two experienced urologists based on the above criteria. Discrepancies between the two researchers will be resolved via discussion with the other senior surgeon. A well-trained researcher will describe and explain the detailed procedure of the study to the patients and answer any questions from them. Patients with written, voluntary, informed consent will be regarded as eligible for the following treatment assignment. An example of the patient consent form is presented as an [online supplementary material](#SP1){ref-type="supplementary-material"}.
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Eligible patients will be randomly divided into two groups: the control group and the PP group according to a 1:1 ratio using a blocked randomisation with randomly varying block size (4 or 6). Participants will be grouped into randomisation blocks by the time and date of surgery. The randomisation will be accomplished using a computer-generated random sequence. The random assignment of each participant will be carried out by two independent researchers, and the serial number will be sealed in an opaque identical envelope, which must not be unfolded until the start of PP. The operator of the pneumoperitoneum machine will open the envelope and deliver the assigned treatment. To avoid potential bias, the surgeons, patients and outcome assessors will be blind to the group allocation.

Intervention {#s2-5}
------------

### PP group {#s2-5-1}

The detailed experimental protocol is presented in [figure 2](#F2){ref-type="fig"}. Participants assigned to the PP group will receive a treatment consisting of three cycles of 5 min insufﬂation and 5 min desufﬂation, after complete anaesthesia and successfully implanting the veress. The pneumoperitoneum machine will be introduced to induce this process, and carbon dioxide gas will be used to maintain the intra-abdominal pressure at 15 mm Hg. The whole duration will last 30 min. The subsequent LPN technique has been described in detail previously,[@R16] and the renal artery will be only clamped rather than the whole pedicle in our surgery.

![Schematic interpretation of the experimental protocol. PP, pneumoperitoneum preconditioning.](bmjopen-2019-032002f02){#F2}

### Control group {#s2-5-2}

Participants in the control group will receive the same placement of the veress but without insufﬂation and subsequent desufﬂation, this process will also similarly last 30 min.

Use of nephrotoxic drugs or other treatments that can lead to renal injury is prohibited during the trial, due to their potential influence on the final results.

Outcome measures {#s2-6}
----------------

### Primary endpoints {#s2-6-1}

\(1\) The change in unilateral (affected kidney and contralateral kidney) and overall GFR detected by ^99m^Tc-diethylenetriaminepentaacetic acid (^99m^Tc-DTPA) renal scintigraphy from baseline to postoperative 1 month and 6 months; (2) change in the level of serum cystatin C (Cys C) from baseline to 12 hours, 24 hours and 48 hours after desufﬂation.

### Secondary endpoints {#s2-6-2}

\(1\) The change in serum creatinine (SCr) from baseline to 12 hours, 24 hours, 48 hours, 1 month and 6 months after desufﬂation; (2) change in postoperative estimated glomerular filtration rate (eGFR) from baseline to 12 hours, 24 hours, 48 hours, 1 month and 6 months after desufﬂation; (3) the change in serum markers for detecting insults of other abdominal organs including ALT, AMS and I-FABP (time frame: from baseline to 12 hours, 24 hours, 48 hours, 1 month and 6 months after desufﬂation); (4) the duration of postoperative hospital stay; (5) the incidence of adverse events (AEs) within 6 months; (6) mortality within 6 months. eGFR will be calculated by a combined formula through serum creatinine: eGFR=186×(SCr)^−1.154^×(age)^−0.203^×0.742 (female) ×1.210 (black).

Additionally, we will also record the following: (1) baseline characteristics of each patients including: age, gender, weight, pre-existing diseases and ASA Score; (2) the tumour characteristics: location, diameter, stage and Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) Score; (3) perioperative data including: anaesthetic drugs (induction and maintenance), the duration of prolonged pneumoperitoneum, warm ischaemia time (WIT) and blood loss; (4) the preoperative baseline levels of GFR, Cys C, SCr, eGFR, ALT, AMS and I-FABP after admission.

The outcomes of all participants at baseline and 12 hours, 24 hours, 48 hours after desufﬂation will be recorded during the hospital stay. At 1 month and 6 months after LPN, patients will be seen at clinic visits for serum examination and GFR detecting. Telephone follow-up will also be performed monthly to monitor their status including AEs.

Data collection and management {#s2-7}
------------------------------

All data will be recorded using a unified report form and collected and maintained in a confidential manner (identifying information of patients will be invisible and each participant will only be labelled by a random code throughout the experiment). All research data will be stored on a fixed server and backed up to another confidential server, with restricted access by primary researchers. Data will be stored for 5 years before being destroyed.

Sample size calculation {#s2-8}
-----------------------

One of the primary objectives of the presently designed study will be the change in GFR of the affected kidney from baseline. Accordingly, we used the following formula according to the Chow *et al*'s textbook[@R17] presuming the change in primary endpoint (GFR) to estimate the required sample size per group:

$n_{A} = \kappa n_{B};n_{B} = \left( {1 + \frac{1}{\kappa}} \right)\left( {\sigma\frac{z_{1 - \alpha/2} + z_{1 - \beta}}{\mu_{A} - \mu_{B}}} \right)^{2};$

$$1 - \beta = \Phi\left( {z - z_{1 - \alpha/2}} \right) + \Phi\left( {- z - z_{1 - \alpha/2}} \right);z = \frac{\mu_{A} - \mu_{B}}{\sigma\sqrt{\frac{1}{n_{A}} + \frac{1}{n_{B}}}}$$

(*κ*=*n*~*A*~/*n*~*B*~ is the matching ratio; *σ* is SD; Φ is the standard normal distribution function; *α* is type I error; *β* is type II error; *μ*~*A*~*−μ*~*B*~ is the mean difference between two groups).

We expect the between-group difference in the absolute change in GFR of the affected kidney from baseline to postoperative 6 months, according to a comprehensive reference to a previous study,[@R18] will be 3.5 mL/min/1.73 m^2^, with a SD of 4.75. We assume a 10% rate of loss to follow-up. Given these assumptions, the t-test will require 43 patients per group to reach 90% power at two-sided α-level of 5%.

Statistical methods {#s2-9}
-------------------

For continuous data which are consistent with the normal distribution, the outcomes will be expressed as mean±SD. Otherwise, the median and IQR will be used. The repeated-measures analysis of variance will be used to determine the differences between the PP and control group over time. Results of Greenhouse-Geisser correction will be reported whenever Mauchly's test of sphericity is significant. The differences between the two groups at each time point will be further evaluated by analysis of covariance with baseline value for each endpoint as a covariate. For binary variables, the χ^2^ test or Fisher's exact will be introduced to explore the potential differences between groups. The kappa coefficient will be introduced to assess the consistency of the selection and data extraction. Imputations methods will be applied to account for missing data. Subgroup analysis with a test of interaction will be conducted to examine heterogeneity of treatment effect. The subgroup variables will include age, gender, PADUA Score and WIT. Results will be considered to be statistically significant at p\<0.05. All data analysis will be performed by separate statisticians from the First Hospital of Nanjing using SPSS software V.24.0, and all of them will be blind to the randomisation and allocation.

Monitoring {#s2-10}
----------

An independent data monitoring committee (DMC) consisting of expert clinicians, statisticians and ethicists will monitor the efficacy and safety of interventions, audit the integrity and overall quality of the data and check the compliance with the protocol. Visits will be monitored monthly during the trial. The DMC is independent of the sponsor and has no competing interests. There will be no interim analysis as the study procedures and data will be regularly checked by the DMC every month. The DMC will discuss the results with the ethics committee and steering committee to decide whether the trial can continue. If there is an unacceptable risk of serious AEs, the study will be ceased.

The monitoring of AE will begin after the start of the detection of preoperative GFR baseline levels, and last 6 months after surgery. The relationship between interventions and AE will be determined by clinical specialist, and all AE will be recorded and included in the trial. Serious AE will be reported to the DMC and ethics committee within 24 hours.

Patient and public involvement {#s2-11}
------------------------------

Patients and the public will not be involved in the process of this study including design, recruitment and conduction. All participants will be informed by a summary of the study results at the end of the trial.

Ethics and dissemination {#s2-12}
------------------------

This study has been approved by the institutional ethics committee of Nanjing First Hospital. Researchers need to explain the detailed experimental process to all participants, and written informed consents must be formally obtained from all patients before randomisation. All participants can freely withdraw from this experiment at any time with no reason. All related research data will be stored securely and not be released externally without the permission of patients.

Regardless of magnitude and trend of the final results, we will report it faithfully through scientific conferences or published articles.

Ancillary and post trial care {#s2-13}
-----------------------------

If patients suffer study-related harm after the trial, free medical care and adequate economic compensation will be provided.

Discussion {#s3}
==========

Renal IRI is inevitable during LPN in most cases and is closely related to the decreased renal function after surgery.[@R4] This signifies the urgency of more protective and practicable approaches. PP is a novel non-pharmacological strategy to induce IP, which can be easily and securely implemented before LPN through mechanical insufﬂation and desufﬂation.[@R11] Encouragingly, PP has been proved to be an effective method for renoprotection against IRI in several animal models,[@R13] and could yield positive effect of reducing oxidative stress after LPN.[@R11] To the best of our knowledge, this trial will be the first clinical attempt to investigate the efficacy of PP in patients with renal tumours after LPN. Participants will be followed for 6 months to detect the short-term and long-term effect of PP.

The performed protocol of PP in our recent study will consist of three cycles of 5 min insufﬂation and 5 min desufﬂation instead of one cycle of 15 min insufﬂation and 15 min desufﬂation as done in previous studies.[@R6] The prolonged insufﬂation with 15 min could cause a lethal injury to abdominal organs before LPN, although the total ischaemia and reperfusion duration of the two procedures are both 30 min. To evaluate the short-term effect of PP on renal function, the postoperative level of Cys C is introduced as one of the primary outcomes, for Cys C is more sensitive than traditional SCr or blood urea nitrogen in the early detection of kidney injury.[@R10] We collect GFR detected by ^99m^Tc-DTPA renal scintigraphy as the primary outcome to assess the unilateral and overall renal function after surgery, because it should be more accurate and specific than eGFR. Additionally, blood ﬂow to the other abdominal viscera will also be decreased during surgical pneumoperitoneum inducing subsequent organ IRI.[@R6] The practical effect of additional pneumoperitoneum on the other abdominal viscera has not been clearly determined. A preclinical study in a porcine model conducted by Avraamidou *et al*[@R21] demonstrated that PP can attenuate damage to the liver and kidney after intra-abdominal hypertension. In the present study, we will observe the levels of ALT, AMS and I-FABP to evaluate the postoperative degree of short-term and long-term insults of the liver, pancreas and intestine, which are more sensitive to IRI.[@R12]

There are several limitations of this study design that should be acknowledged. First, our trial is a single-centre study, which may not be generalisable to other centres. Second, the function of kidney and other organs will only be evaluated by outcomes measured within 6 months of treatment. Finally, WIT cannot be unified in common with standardised animal experiments, for it is closely associated with the characteristics of the tumours and the complexity of surgery.

In summary, this will be the first RCT to detect the renoprotective role of PP in patients undergoing LPN and assist with the determination of effective strategies for the prevention of IRI. The results yielded from this study will be helpful to improve the overall efficacy of LPN for patients with renal tumours.
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